| Document |
Document Title |
|
WO/2017/156432A1 |
The present disclosure provides edible compositions comprising Formulas and compounds of steviol glycoside esters, or combinations thereof, which are suitable for use as sweeteners, for example, by incorporation into edible compositions....
|
|
WO/2017/153538A1 |
The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.
|
|
WO/2017/144318A1 |
The invention relates to derivatives of rhamnolipids of formula (I), formulations containing same, and the use thereof, in particular for scent retention on hair.
|
|
WO/2017/144099A1 |
The present invention relates to a compound of formula (I) wherein the substituents are as defined in the claims. Said compound may be used as a ligand in order to purify glycosylated bio molecules. The present invention further relates ...
|
|
WO/2017/144317A1 |
The invention relates to ester derivatives of rhamnolipids of formula (I) as nonionic surfactants, formulations containing same, and the use thereof.
|
|
WO/2017/143956A1 |
The present invention relates to a naturally-extracted high potency sweetener rebaudioside, and particularly relates to a novel crystal form of a sodium salt of rebaudioside B and a preparation method thereof. The novel crystal form is c...
|
|
WO/2017/134176A1 |
The present invention relates to a process for producing 2'-O-fucosyllactose, to the intermediates obtainable by this process and to the use of these intermediates. Production comprises the reaction of a protected fucose of general formu...
|
|
WO/2017/132755A1 |
The present disclosure provides: floridoside or isethionic acid for use as an antibiotic potentiator; floridoside or isethionic acid in a combination therapy with an antibiotic compound; as well as methods of potentiating the antibiotic ...
|
|
WO/2017/130191A1 |
The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and π* acceptor group-containing dioxetane based chemiluminescence probes, and com...
|
|
WO/2017/131236A1 |
The present invention relates to the nucleic acid complex expressed by formula 1. Formula 1: (In formula 1, X is an oligonucleotide, L1 and L2 each independently represents a sugar ligand, and S1, S2 and S3 each independently represents ...
|
|
WO/2017/129752A1 |
The present invention relates to neisserial LPS having a tetra-acylated lipid A moiety, wherein the tetra-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it lacks one of the sec...
|
|
WO/2017/129761A1 |
The present invention relates to neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it comprises a palmitoleo...
|
|
WO/2017/132469A1 |
Various aspects of the invention relate to compositions comprising C-2a gentamicin. A composition may be substantially free from one or more of C-1 gentamicin, C-1a gentamicin, C-2 gentamicin, C-2b gentamicin, gentamicin A, gentamicin B,...
|
|
WO/2017/130217A1 |
The present invention relates to process for the preparation of D-glucitol, 1,5- anhydro-l-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]
phenyl] methyl]phenyl]-, (1S) formula- 1 and its crystalline forms thereof.
|
|
WO/2017/126969A1 |
The invention pertains to a method for the etherification of a carbohydrate, comprising subjecting the carbohydrate to superheated steam under alkaline conditions in the presence of an etherification agent to obtain a carbohydrate ether.
|
|
WO/2017/127422A1 |
Compounds, compositions, and methods for the diagnosis and/or treaimeni of medical conditions involving infections with and colonization by Fseudomonas bacteria including, for example, Fseudomonas aeruginosa in the lungs of patients with...
|
|
WO/2017/124970A1 |
Provided are a dicaffeoyl-spermidine derivative glycoside, a preparation method therefor and a use. Biological activity tests show that the dicaffeoyl-spermidine derivative glycoside has antioxidant activity and antiviral activity, the a...
|
|
WO/2017/120729A1 |
The present invention discloses a method and an intermediate for the preparation of an epirubicin hydrochloride. The method comprises the following step: in an organic solvent and under an action of an alkali, subjecting compound 4 and a...
|
|
WO/2017/122495A1 |
A ceramidase inhibitor which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a ceramide synthesis promoter which comprises a compound represented by formula (II) or a pharmaceutically ac...
|
|
WO/2017/123809A1 |
The invention relates to compounds for inhibiting a cancer cell or a virus. Particularly, the invention provides compounds for inhibiting, treating and/or preventing cancer and Zika virus.
|
|
WO/2017/118968A1 |
Novel aminoglycosides, represented by Formulae (I), (Ia), (III) and (IIIa), as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical composition...
|
|
WO/2017/120480A1 |
A method for making a highly soluble stevio! glycoside composition is described. The resulting composition readily provides solutions with at least 0,5% concentration.
|
|
WO/2017/120524A1 |
Provided herein include methods and compositions for synthesis of Lipid IVA and derivatives thereof, using a defined set of pathway enzyme, which may be isolated and used to reconstitute all or part of the pathway in a cell-free reaction.
|
|
WO/2017/119700A1 |
The present invention relates to a C-glucoside derivative containing a fused phenyl ring or a pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition comprising the same, a use thereof, an...
|
|
WO/2017/118967A1 |
Novel aminoglycosides, represented by Formulae (Ia) and (Ib), as defined in the instant specification, are disclosed. Also disclosed are pharmaceutical compositions containing the same, and uses thereof in the treatment of medical condit...
|
|
WO/2017/116799A1 |
An exemplary embodiment provides a method of treating an environment (aquatic or land) to remediate an infestation of mollusks, either active or in hibernation, to remediate a mollusk infestation. The method includes the steps of: select...
|
|
WO/2017/109023A1 |
The present invention relates to a method of preparing an oligosaccharide composition, said method comprising the steps of: (a)providing a pectin; and (b)performing, in any order, conversion of carboxylic acid groups to the corresponding...
|
|
WO/2017/109288A1 |
The present invention relates to im-munostimulatory compounds of the following formula, combinations thereof, pharmaceutical or nutritional preparations comprising the same, as well as their use for modulating T helper (Th) and T regulat...
|
|
WO/2017/103211A1 |
The present invention relates to a synthetic saccharide of general formula (I) that is related to Streptococcus pneumoniaeserotype 2 capsular polysaccharide, a conjugate thereofand the use of said saccharide and conjugatefor raising a pr...
|
|
WO/2017/106577A1 |
Steviol glycoside compositions having improved sweetness and flavor profiles are described.
|
|
WO/2017/104897A1 |
The present invention relates to a Tris- or neopentyl glycol-based amphipathic compound, a method for producing same, and a method for extracting, emulsifying, stabilizing or crystallizing a membrane protein by means of the amphipathic c...
|
|
WO/2017/098175A1 |
The present invention relates to a novel process for preparing compositions comprising alkyl(alkyl-glucoside)uronates, from biobased or biocompatible/biodegradable raw materials, and also salts and acids thereof.
|
|
WO/2017/098174A1 |
The present invention relates to a novel method for obtaining surfactant compositions made from alkyl-L-guluronamides or mixtures of L-guluronamides and D-mannuronamides, the compositions obtained by said method and the uses thereof.
|
|
WO/2017/093276A1 |
The present invention relates to L-arabino-oligosaccharides, in particular synthetically produced L-arabino-oligosaccharides and their uses for the prophylaxis of allergic reactions in mammals.
|
|
WO/2017/095237A1 |
The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to prot...
|
|
WO/2017/095904A1 |
Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin ...
|
|
WO/2017/088058A1 |
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer and increasing cellular internalization of said peptide compounds. The peptide compounds are selected fr...
|
|
WO/2017/091544A1 |
The invention provides compounds of formula (I) which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions...
|
|
WO/2017/083967A1 |
The present invention provides purified compounds extracted from seaweeds having the formula (I): wherein R1 and R2 is each independently H or a fatty acid and their use for inhibiting the growth of cancer cells.
|
|
WO/2017/084987A1 |
The invention comprises Gal NAc phosphoramidite derivatives of the formula (I), wherein R1 is a hydroxy protecting group, n is an integer from 0 to 10 and m is an integer from 0 to 20 and its corresponding enantiomers and/ or optical iso...
|
|
WO/2017/075994A1 |
Provided are a separation and purification method for epirubicin or hydrochloride thereof. The method comprises: 1) taking epirubicin or a hydrochloride crude product thereof, and sampling macroporous absorption resin; and 2) carrying ou...
|
|
WO/2017/079582A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and ...
|
|
WO/2017/078609A1 |
The present invention relates to a metal-organic framework with encapsulated target-molecule, a process for the preparation of a metal-organic framework with encapsulated target-molecule, as well as the metal-organic framework with encap...
|
|
WO/2017/078097A1 |
Provided is a method for stably producing (2S)-2-hydroxydibekacin, said method being characterized by the use of 2-hydroxykanamycin C or 2-hydroxykanamycin B as a starting material or synthetic intermediate.
|
|
WO/2017/078098A1 |
Provided is a method for stably producing (2S)-2-hydroxydibekacin, said method being characterized by the use of 2-hydroxykanamycin C or 2-hydroxykanamycin B as a starting material or synthetic intermediate.
|
|
WO/2017/078096A1 |
Provided is a method for efficiently producing a compound represented by formula II, namely (2S)-2-hydroxyarbekacin or a salt thereof from (2S)-2-hydroxydibekacin represented by formula I or a salt thereof, which is characterized by usin...
|
|
WO/2017/071152A1 |
Provided are a phosphoryl mannose pentasaccharide as shown in formula (I) and derivatives of the phosphoryl mannose pentasaccharide as shown in formulas (II)-(XI), and a preparation method thereof. In the preparation method of this inven...
|
|
WO/2017/063617A1 |
The present invention relates to a preparation method of the intermediates of structures la (for the synthesis of canagliflozin) and 1b (for the synthesis of dapagliflozin), where in structure la X is methyl and Ar represents 2-(5-(4-flu...
|
|
WO/2017/062800A1 |
Disclosed are compounds for the selective labeling of cell-surface sugars in cancer cells. The compounds are activatable by triggers specific to cancer cells, and, when metabolized, label a cancer cell surface sugar with an azide chemica...
|
|
WO/2017/058474A1 |
Prepare a branched alcohol-based sugar surfactant by: (a) providing an ether alcohol and a fully acetylated sugar where the ether alcohol has the structure of Structure (I); (b) coupling the ether alcohol with the acetylated sugar in the...
|
